Bide Pharmatech Co. Ltd. Class A
SSSE:68807357.61
CNY
-3.85
(-6.26%)
ISIN
CNE100005NV3
Return %
Stock
S&P 500
1Y
-14.77
14.20
3Y
-14.19
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Lan Dai
- Full Time Employees
- 734
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shanghai China
- IPO Date
- Oct 11, 2022
- Website
- bidepharmatech.com
- Similar Companies
- Business
- Bide Pharmatech Co. Ltd. is a China-based pharmaceutical research and development services provider and chemical product developer that specializes in the design, development, manufacturing, and commercialization of molecular building blocks and functional chemical reagents for early-stage drug discovery and life sciences research. Founded in 2007 and headquartered in Shanghai, China, the company operates primarily within the specialty chemicals and pharmaceutical outsourcing sector, serving global pharmaceutical corporations, biotechnology enterprises, contract research organizations, and academic and scientific research institutes. The company's core product and service offerings comprise molecular building blocks, including heterocyclic compounds, aliphatic building blocks, aromatic derivatives, fluorinated building blocks, chiral building blocks, boronic acids, amino acid derivatives, and specialized chemical linkers for proteolysis targeting chimeras (PROTACs) and antibody-drug conjugates (ADCs); specialty functional reagents, including organometallic catalysts, ligands, coupling reagents, biochemical reagents, and high-purity analytical standards; custom synthesis services, spanning custom chemical synthesis from milligram-scale research quantities to kilogram-scale batches; and contract process development and manufacturing services for novel chemical scaffolds and advanced pharmaceutical intermediates. Bide Pharmatech operates an international sales and distribution network supported by digital procurement platforms, localized customer support offices, and regional warehousing hubs across mainland China, North America, Europe, and the Asia-Pacific region, including overseas operations in the United States, Germany, and India. In recent operational developments, the company has broadened its global footprint by expanding its overseas warehousing network and localized distribution infrastructure across Europe and North America to accelerate delivery lead times; broadened its high-value product portfolio with targeted expansions into new drug modalities, specifically ADC payload-linker systems and oligonucleotide synthesis building blocks; and upgraded its automated synthesis laboratories and continuous flow chemistry facilities to enhance process efficiency and high-throughput production capacity.